Bone pain is a common and severe symptom in cancer patients. The present study employed a mouse model of leukemia bone pain by injection K562 cells into tibia of mouse to evaluate the analgesia effects of Lappaconitine. Our results showed that the lappaconitine treatment at day 15, 17 and 19 could effectively reduce the spontaneous pain scoring values, restore reduced degree in the inclined-plate test induced by injection of K562 cells, as well as restore paw mechanical withdrawal threshold and paw withdrawal thermal latency induced by injection of K562 cells to normal group levels. Additionally, the molecular mechanisms of lappaconitine's analgesia effects may be related to affect the expressive levels of endogenous opioid system genes (POMC, PENK and MOR), as well as apoptosis-related genes (Xiap, Smac, Bim, NF-κB and p53). Our present results indicated that lappaconitine may become a new analgesia agent for pain management induced by leukemia cells. Bone pain is a common and severe symptom in cancer patients. The present study employed a 17 mouse model of leukemia bone pain by injection K562 cells into tibia of mouse to evaluate the 18 analgesia effects of Lappaconitine. Our results showed that the lappaconitine treatment at day 15, 17 19 and 19 could effectively reduce the spontaneous pain scoring values, restore reduced degree in the 20 inclined-plate test induced by injection of K562 cells, as well as restore paw mechanical withdrawal 21 threshold and paw withdrawal thermal latency induced by injection of K562 cells to normal group 22 levels. Additionally, the molecular mechanisms of lappaconitine's analgesia effects may be related to 23 affect the expressive levels of endogenous opioid system genes (POMC, PENK and MOR), as well as 24 apoptosis-related genes (Xiap, Smac, Bim, NF-κB and p53). Our present results indicated that 25 lappaconitine may become a new analgesia agent for pain management induced by leukemia cells.
Introduction

29
Bone pain is a common and severe symptom in cancer patients, especially in advanced stage 30 (Jimenez-Andrade et al., 2010; Kane et al., 2015; Mantyh, 2014; Mantyh & Hunt, 2004) . Many 31 patients with hematological malignancies (leukemia, lymphoma, myeloma, myelodysplastic syndromes 32 and myeloproliferative neoplasms) experienced the pain frequently (Niscola et al., 2011) . Currently the 33 molecular mechanisms underlying leukemia bone pain are largely unknown. The available 34 pharmacological tools for bone pain analgesia are limited, with unstable efficacy, and sometimes 35 adverse side effects (Kane et al., 2015; Mantyh, 2014) . Therefore it is important to search for new 36 therapeutic drugs against leukemia bone pain, especially from traditional Chinese medicine (TCM) 37 agents.
38
Aconitum (Wu Tou) is a common TCM drug used for analgesia (Singhuber et al., 2009 ). 39 Lappaconitine is one bioactive component isolated from aconitum sinomonatum nakai with clinical 40 efficacy in chronic pain and inflammation (Ono & Satoh, 1988; 1991; Wang et al., 2009; , 41 which is the most effective drug presently available for the treatment of malignant tumor and other 42 intractable pain . Using methods for screening of analgesics, the results obtained 43 from One and Satoh showed that the analgesic effects of lappaconitine were generally about 2 to 5 44 times less than those of morphine (Ono & Satoh, 1988; 1989; 1990) .The use of lappaconitine reduces 45 pain in liver cancer patients, and can alleviate their dependence on morphine treatment (Chen et al., 46 1996; Liu et al., 1987) . In addition, lappaconitine shows no addition properties, nor toxicity against 47 nervous system and heart (Henbach & Hunt, 2004) . However, there is no report about the effect of 48 lappaconitine on pain induced by leukemia cells. The present study aimed to examine the potential 49 application of lappaconitine in leukemia bone pain. The study has been approved by ethic committee of animal research in Hangzhou Normal University. 80 female ICR mouse were provided by animal center in Hangzhou normal university with free 63 access to food and water (12/12 h light cycle, 5 mouse in each cage). The animals were randomly 64 assigned into 4 groups: normal group (n=20), normal saline group (n=20), bone pain group (K562 cell 65 transplanted group) (n=20), and bone pain with lappaconitine treatment group (K562 66 cells+lappaconitine group) (n=20).
The leukemia bone pain model was built through injection of chronic myeloid leukemia K562 cells 69 into tibial bone marrow cavity directly. Briefly, the animals were anesthetized with halothane and 70 placed in supine position. The amount of 4×10 5 (1X10 7 /ml, 40 µl) K562 leukemia cancer cells or same 71 volume of saline were infused into the left tibia marrow cavity through a microsyringe. The puncture 72 was sealed by the medical glue and the wound area was smeared with erythromycin eye ointment in 73 accordance with the protocols of aseptic operation. The animals were let for recovery in a warm place 74 before sending back to home cage. The lappaconitine (Maya Co., Shanghai) were given through intraperitoneal (i.p.) injection at 4 79 mg/kg on day 15, day 17, and day 19 after cancer cell transplantation. 
89
For inclined plate test to assess the muscular strength and the proprioception according to previous 90 methods , the mouse were placed on the inclined plane, in vertical position to the long 91 axis. If the mouse could keep balance for 5 seconds, the inclined degree will be increased by 2 degree 92 with an initial angle of 30°. The loss-balance degree for the inclined plate was recorded.
94
For the paw mechanical withdrawal threshold (PMWT) measurement, von Frey hair (Stoelting, 95 Wooddale, US) was used as described previously (Kim & Chung, 1992) . A series of von Frey hair 96 (0.16 g, 0.4 g, 0.6g 1.0 g, 1.4 g, 2.0 g, 4.0 g, 6.0 g) were employed to stimulate the left foot center 97 according to up-and-down approach, starting from 0.4 g. The non-response was recorded as "O" and 98 response as "X". 50% PMWT (g) = 10 log (f)+kδ . δ is taken as 0.224 in present study, and k is taken from 99 the scale based on "O" and 'X" recordings.
101
For paw withdrawal thermal latency (PWTL) measurement, YLS-21A cold-hot plate was used. The 102 mouse were placed on 55 degree hot plate and the pain response (limb licking or lifting) latencies were 103 recorded. Each mouse was tested for 5 times with 10 minutes interval. The average of three median 104 values was recorded.
106
For tail illumination pain test of tail-flick latency, the mouse tail was illuminated under 30W light 107 and the latency for tail flick was recorded. Each mouse was tested for 5 times with 10 minutes interval. 108 The average of three median values was recorded. The total RNA was extracted from the tibial bone marrow cells using TRlzol Reagent (Invitrogen 113 Corp., Carlsbad, CA) according to the manufacturer's instructions. Two μg of total RNA in each group 114 was reverse transcribed into cDNA in a final volume of 50 μl as our previous report (Fu et al., 2014;  115 Zhang et al., 2014 Each group consisted of 20 mouse. The data were represented as mean ± SEM and analyzed with a 124 one-way analysis of variance (ANOVA) followed by the Dunnett's test (two-sided) for post hoc 125 comparisons on all time course studies. A probability level of less than 0.05 was considered significant. There was no clear difference between control and the bone pain group until 5 days after K562 cell 133 transplantation. Then the bone pain group mouse began to exhibit reduced spontaneous activity, and 134 decreased ground touch for the affected limb. The body weights in four groups had no differences 135 except for day 5, in which the body weight of inoculative groups was decreased markedly, indicating 136 that the inoculation technology may affect the appetite in the first few days, as shown in Figure 1 . For spontaneous pain scoring, all mouse in each group moved in a normal way in prior to the 141 manipulation. The infusion technique caused limp movement just on day 1 in all the infusion groups. 142 The K562 cell transplanted group exhibited spontaneous pain which was began at 7-9 days after 143 injection of K562 cells, lasting for the rest of the experiment; the treatment with lappaconitine at 4 144 mg/kg on day 15, 17 and 19 could reduced the spontaneous pain moderately but not completely ( Figure  145 2 Inclined-plate test was employed to evaluate the muscle functioning and the body balance behavior. 150 The degree that mouse could maintain the balance was reduced markedly after 9 days in the K562 cells 151 transplanted group, which was restored by lappaconitine treatment on day 15, 17 and 19 (Figure 3 , 152 ***P<0.001 compared with the control groups).
154
The von Frey hair tests and the hot plate tests were used to assess the sensitivity of mouse paw to 155 mechanical (Figure 4 ) and thermal ( Figure 5 ) stimulation, respectively. Our results showed that both 156 the paw mechanical withdrawal threshold (PMWT)and the paw withdrawal thermal latency (PWTL) 157 were decreased significantly after 7-9 days in the K562 cells transplanted group and lappaconitine 158 treatment on day 15, 17 and 19 could also restored both the PWTL and PMWT values to the levels of 159 control groups, respectively which was similar to the previous pain behavior tests (Figure 4 and Figure  160 5, * P<0.05, ** P<0.01, *** P<0.001, compared with control groups).
For tail illumination pain test of tail-flick latency, no clear differences were observed among the four 163 groups mentioned above, suggesting that this kind of pain behavior might be deficit in present animal 164 model of cancer bone pain (Figure 6 ). Several target genes of endogenous opioid system (POMC, PENK and MOR), apoptosis-related 169 genes (Xiap, Smac, Bim, NF-κB and p53), and neurokinin receptor 1 (NK1R) gene were detected to 170 explore the potential molecular mechanisms involved in our leukemia bone cancer pain. In these 171 indicated target genes, our results showed that the expression levels of these target genes were 172 decreased markedly except for the Xiap gene that was increased markedly in the K562 cells 173 transplanted group, while lappaconitine treatment could return their expression levels to the control 174 group levels or raised their expression levels markedly (Figure 7 , **P<0.01, ***P<0.001, compared 175 with the control group of each gene). The number of cancer patients is growing and 60-90% of late stage patients suffered from cancer 180 pain, including 30% of patients with severe lasting pain (Buga & Sarria, 2012; Kane et al., 2015; 181 Mantyh, 2014 
